Clinical Evaluation of Zomepirac in the Treatment of Chronic Pain

ABSTRACT

This study demonstrates that the nonnarcotic analgesic Zomepirac sodium administered in repeated doses is well tolerated and effective in 42 patients with mild to severe chronic pain. When the relative incidence of side effects such as gastrointestinal up set and central nervous system disturbances are taken into account, Zomepirac is clearly the preferable therapeutic agent. We therefore, suggest that Zomepirac is an acceptable nonnarcotic agent for the management of chronic pain and that its efficacy and safety profile are consistent with current postsurgical managements including early ambulation.